GlassScriptPhysician profile
Jack Andrew Payne
NPI 1548021801
$3,317.64
in general payments reported to CMS, 2019-2025
23 companies · $1,844 in 2025
The $1,844 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,474 · 2025: $1,844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,317.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $777.08 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $504.28 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $437.32 | 2024-2025 | |
| Lilly USA, LLC | $194.09 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $175.91 | 2024-2025 | |
| Philips North America LLC | $144.01 | 2025 | Labosys |
| Cagent Vascular INC | $144.00 | 2025 | Serrantor |
| Glaxosmithkline, LLC. | $117.92 | 2024-2025 | Arexvy, Trelegy Ellipta |
| Corcept Therapeutics | $116.32 | 2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $95.42 | 2024-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.16 | 2024-2025 | Jardiance |
| Amgen INC. | $78.17 | 2024-2025 | Repatha, Repatha, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $77.50 | 2025 | Caplyta |
| Exact Sciences Corporation | $73.22 | 2024-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $71.10 | 2024-2025 | Veozah |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $49.41 | 2024-2025 | Wavewriter Alpha Prime 16 |
| Shield Therapeutics INC | $41.27 | 2024 | |
| Esperion Therapeutics, INC. | $37.05 | 2024-2025 | Nexletol |
| Vanda Pharmaceuticals INC. | $29.55 | 2025 | Fanapt, Hetlioz |
| Organogenesis INC. | $23.92 | 2024 | Affinity |
| Seqirus USA INC | $20.92 | 2024 | Fluad, Flucelvax |
| C2n Diagnostics, LLC | $16.12 | 2025 | Precivityad2 |
| Currax Pharmaceuticals LLC | $13.90 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Payne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.